)
Biomea Fusion (BMEA) investor relations material
Biomea Fusion 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic focus and pipeline overview
Two main assets in development: icovamenib, a selective oral menin inhibitor for diabetes, and BMF-650, an oral GLP-1 receptor agonist for weight loss, with GLP-131 also in Phase 1 for obesity.
Shifted focus to diabetes and obesity, targeting disease progression and beta-cell failure rather than just symptoms.
Icovamenib aims to restore beta cell function and insulin production, with preclinical and clinical data supporting increased insulin secretion and beta-cell mass.
BMF-650 and GLP-131 are designed for improved bioavailability and efficacy, with significant weight loss in preclinical models and favorable liver safety profiles.
Clinical data and efficacy
Icovamenib showed sustained A1C/HbA1c reduction up to 52 weeks post-treatment, with a 1.5% placebo-adjusted drop and durable effects beyond 12 weeks.
Increased C-peptide and insulin transcript levels indicate enhanced insulin secretion and beta cell regeneration.
Significant A1C reduction observed in patients failing GLP-1 therapy, with effects persisting after dosing.
Higher drug exposure correlates with greater A1C reduction; future dosing will require administration with food for optimal exposure.
Safety and tolerability
Icovamenib was generally well-tolerated over 52 weeks, with adverse event rates similar to placebo and no treatment-related serious adverse events or discontinuations.
Most common adverse events included mild diarrhea, headache, and transient liver enzyme elevations, all resolving without treatment interruption.
BMF-650 and GLP-131 showed no ALT/AST elevations in preclinical and early clinical studies.
Next Biomea Fusion earnings date
Next Biomea Fusion earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)